Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

EVA Magnetoelectric 3D printing technology - the revolution of actuatable composites

Coordinator
Universitat De Barcelona, Spain
Runs
1 October 2022 to 30 September 2026
Status
Running
EU funding
€2.1m
Total cost
€2.1m
Partners
9 organisations in 5 countries
Type
European Innovation Council
Grant agreement
101047081

What the project is doing

In the project's own words, from its summary on CORDIS.

The EVA project puts forward a radically new 3D printing technology that will revolutionize the nature of composites, transforming them from passive elements to responsive systems that can be instructed to execute tasks – on command. A technology that can program the mechanical, magnetic and electrical anisotropy of 3D printed structures in any direction, to fabricate systems that can be wirelessly actuated to elicit variable electrical responses during operation.

Such unprecedented control over the properties and active functionalities of the printed systems will offer great advantages in multiple applications such as biotechnology (e.g. scaffolds to stimulate growth and differentiation of stem cells – 1st proof-of-principle), wastewater treatment (e.g. high-efficiency catalytic membrane to free wastewaters from persistent micropollutants – 2nd proof-of-principle), next-generation robotics, security and future data-storage technologies.

EVA technology will empower engineers, researchers, and industrialists wanting to develop new concepts, materials, or functional devices to fine-tune matter at will with an affordable table-top solution. A technology enabling a new generation of multifunctional actuatable composites that can be printed and leveraged to develop radically new applications impacting multiple sectors of the economy. The potential of EVA project to achieve a proof-of-principle, and validate the scientific basis of the proposed breakthrough technology through this PATHFINDER call, is shown by the immediate endorsement from respected stakeholders, e.g. multinational corporations (Siemens) and disruptive SMEs (Nanoscribe & Transpharmation), policy makers, health professionals’ organisations, patients’ associations, and end-users (healthcare and water treatment facilities).

These stakeholders will play vital advisory roles on the feasibility, transferability and exploitability of the proposed technology.

Topics

Who is involved

OrganisationCityCountryRole
Universitat De BarcelonaBarcelonaSpainCoordinator
Eidgenoessische Technische Hochschule ZuerichZuerichSwitzerlandAssociatedpartner
Magnebotix AGZurichSwitzerlandAssociatedpartner
Idrima Epistimon Kai Erevnas MkoDimos MonofatsiouGreeceParticipant
Idryma Epistimon Kai Erevnas I.k.e.IraklionGreeceParticipant
Universidad Autonoma De MadridMadridSpainParticipant
Stratasys LtdRehovotIsraelParticipant
The Hebrew University of JerusalemJerusalemIsraelParticipant
Experian LdaPortoPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI